

OPEN Gold(I/III)-Phosphine Complexes as Potent Antiproliferative Agents

Jong Hyun Kim, Evan Reeder, Sean Parkin & Samuel G. Awuah

The reaction of gold reagents [$\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$], $[\text{AuCl}(\text{tth})]$, or cyclometalated gold(III) precursor, $[\text{C}^{\wedge}\text{NAuCl}_2]$ with chiral ((R,R)-(-)-2,3-bis(*t*-butylmethylphosphino) quinoxaline) and non-chiral phosphine (1,2-Bis(diphenylphosphino)ethane, dppe) ligands lead to distorted Au(I), (1, 2, 4, 5) and novel cyclometalated Au(III) complexes (3, 6). These gold compounds were characterized by multinuclear NMR, microanalysis, mass spectrometry, and X-ray crystallography. The inherent electrochemical properties of the gold complexes were also studied by cyclic voltammetry and theoretical insight of the complexes was gained by density functional theory and TD-DFT calculations. The complexes effectively kill cancer cells with IC_{50} in the range of ~ 0.10 – $2.53 \mu\text{M}$ across K562, H460, and OVCAR8 cell lines. In addition, the retinal pigment epithelial cell line, RPE-Neo was used as a healthy cell line for comparison. Differential cellular uptake in cancer cells was observed for the compounds by measuring the intracellular accumulation of gold using ICP-OES. Furthermore, the compounds trigger early – late stage apoptosis through potential disruption of redox homeostasis. Complexes 1 and 3 induce predominant G1 cell cycle arrest. Results presented in this report suggest that stable gold-phosphine complexes with variable oxidation states hold promise in anticancer drug discovery and need further development.

Gold-based probe development and drug discovery remain a burgeoning area of biological research and treatment for disease indications such as cancer^{1–5}, arthritis^{6–9}, and microbial infection^{10,11} following the FDA approval of tetra-*O*-acetylglucose-1-thiolgold(I) triethylphosphine complex (auranofin). Exploring the Au(I) and Au(III) chemical space has given rise to enormous diversity of gold compounds of biological relevance, influenced by creative ligand design^{12–16}. Despite effective clinical and preclinical treatment of cancer and rheumatoid arthritis by gold complexes such as auranofin, the molecular basis of drug action remains unclear for gold(III) phosphine compounds present in this report. Years of research implicates a number of disease targets including: (i) proteasome-associated deubiquitinases^{6–9}; (ii) thiol-rich enzymes such as thioredoxin and glutathione reductase^{17–20}; (iii) thiol-dependent proteases²¹; iv) autophagy induction²²; and superoxide/oxyradical ion generation²³.

Auranofin, which is under clinical and preclinical investigation for the treatment of a variety of cancers including leukemia^{24,25} and ovarian malignancies^{26–28} as well as microbial infections^{29–31} is a phosphinogold complex. This has accelerated the development and discovery of several gold-phosphine complexes for therapeutic applications. Gold(I)-phosphine anti-cancer complexes have been identified to trigger apoptosis by targeting the mitochondria and inhibiting thioredoxin reductase^{32–34}. Structural diversity of gold complexes bearing phosphine ligands have important implications for anticancer activity and probe development^{20,35}. Work by Berners-Price *et al.* demonstrated the anticancer effect of gold-phosphine complexes and have also tried to improve the *in vitro* and *in vivo* efficacy of this class of compounds^{2,5,36–42}. Gold complexes bearing dithiocarbamate^{43–45} and triorganophosphine ligands^{33,46} of the type $[(\text{R}_3\text{P})_2 \text{Au}(\text{S}_2\text{CNR}_2)]$ display anticancer activity across a panel of cancer cells including ovarian cancer cells⁴⁷. Recently, Darkwa and co-workers synthesized dinuclear phosphinogold(I) complexes bearing varied phosphine ligands including triphenylphosphine, and diphenylphosphino-alkanes and dithiocarbamates of the type $[\text{Au}_2\text{Cl}_2(\text{dppe})]$ and evaluated their anticancer activity⁴⁷. The complexes displayed broad spectrum of activity in a number of cancer cell lines. Additionally, the anticancer activity of phosphinogold(I) complexes bearing thioglucose ligands as in the case of auranofin show higher potency than their thiolate counterparts even in cisplatin resistant cells. For example, the P – Au – S structural motif is prevalent in a number of gold-phosphine complexes such as the lupinylsulfide (OmS) or sulfanylpropenoate (sppa)⁴⁸ containing phosphinogold(I), $[\text{AuOmS}](\text{Ph}_2\text{P}(\text{CH}_2)_2\text{PPh}_2)$ or $[\text{Au}(\text{PPh}_3)(\text{sppa})]$, respectively and they exhibit good anticancer activity⁴⁹. Improving the biological activity of gold-phosphine complexes require ligand tuning that expand diversity, lipophilicity, physiological stability, and high selective cytotoxicity in cancer cells over normal cells^{50,51}.

Department of Chemistry, University of Kentucky, 505 Rose St., Lexington, KY, 40506, USA. Correspondence and requests for materials should be addressed to S.G.A. (email: awuah@uky.edu)

Received: 17 May 2019

Accepted: 7 August 2019

Published online: 26 August 2019

Whereas a lot of work has been conducted with linear phosphinogold(I), its high oxidation state counterpart gold(III) needs further exploration. Recent advancement of cyclometalated gold(III) in anticancer development show promising results^{1,52–55}. These ligands impart strong σ -donating character to the gold center for stability and offer the possibility of different ligands around the metal center, given its square-planar geometry⁵⁶. Che and co-workers showed that dinuclear cyclometalated gold(III) phosphine, [(C[^]N[^]C)₂Au₂(μ -dppp)]CF₃SO₃)₂ inhibit hepatocellular carcinoma *in vivo* by inducing ER stress⁵⁷. There still remains the need to expand the structural diversity of gold-phosphine complexes by designing new gold(III)-phosphine complexes.

Another important feature of ligands in the context of biological efficacy is chirality, since they possess the property to tune substrates to respective biological targets for improved target engagement that may be elusive for non-chiral ones. The use of chiral ligands in gold drug discovery remain largely unexplored. Incorporating chiral ligands into gold(I) or gold(III) complexes will expand the chemical space to further opportunities in medicinal inorganic chemistry.

In this report, we synthesized gold(I) complexes bearing chiral or achiral phosphine ligands and in addition mononuclear (C[^]N)-cyclometalated gold(III) bearing chiral or achiral phosphine ligands. The complexes display potent cytotoxic activity in different cancer cell lines by triggering apoptosis through ROS induction. The study establishes the need for a broader scope of gold complexes for cancer therapy.

Results and Discussion

Rationale and approach. Stabilizing the gold metal center for biological utility remains an important aspect of metallodrug discovery. Gold compounds possess high redox potential (i.e. Au⁺³ + 2e⁻ → Au⁺¹ E° = 1.41 V and Au⁺¹ + e⁻ → Au_(s) E° = 1.69 V)⁵⁸. This is due to relativistic effects. Often, strong σ -donating ligands such as phosphines and N-heterocyclic carbenes are used to improved stability of gold complexes against rapid reduction⁵⁹. The polarizable nature of gold, owing to its loosely held electrons facilitates its coordination to soft Lewis bases such as phosphorus, sulfur containing ligands. Linear gold(I) complexes are limited by their low coordination number. On the other hand, gold(III) compounds largely exist in a square-planar configuration and provides increased number of coordination sites. This can be harnessed for the development of anticancer agents bearing multidentate ligands with enhanced stability and activity. In addition the use of chiral phosphine ligands in gold scaffolds and their effects on geometry remains underdeveloped. A study that examines the effect of oxidation states of compounds bearing phosphine ligands will be beneficial. We envisioned the investigation of gold(I)/(III)-phosphino complexes as potential anticancer agents to offer preliminary structure-activity insights of gold-based metallodrugs. These gold(I)/(III) complexes could interact with biological targets, such as proteins, in a similar fashion to reported gold-phosphino complexes but with optimal kinetic lability to avoid premature deactivation. Within this context, work that studied the anticancer potential of gold-phosphino complexes offered impetus that the complexes synthesized in our laboratory will be active against cancer cells *in vitro*. Furthermore, the distorted gold(I) with phosphine ligands as well as gold(III) complexes bearing cyclometalated and phosphine ligands could exhibit the needed stability for effective therapeutic response, even in drug-resistant cancer.

The design of our compound library employed the use of the chiral (R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline and achiral 1,2-bis(diphenylphosphino)ethane (DPPE) phosphine ligands due to their biocompatibility and moderate lipophilicity when present coordination complexes or as ancillary ligands in organometallic compounds. For further investigation into the geometry and oxidation states of these complexes and their effects on anticancer activity, we explored the synthesis of dinuclear gold(I) complexes and (C[^]N)-cyclometalated backbone for the formation of an organometallic gold(III), all bearing phosphine ligands used in this study. We hypothesized that the small set of compounds with rich diversity including, ligand type, stereochemistry, oxidation state, geometry and distortion, would possess interesting biological properties for gold-based drug discovery.

Synthesis and characterization. The gold-phosphine complexes under investigation in this study are depicted in Fig. 1. The chiral phosphine ligand, (R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline⁶⁰, which is well tolerated in mice was used for the synthesis of the respective Au(I) and Au(III) compounds, using tetrachloroauric acid trihydrate (HAuCl₄·3H₂O) or AuCl(tht), or (C,N)-cyclometalated Au(III)Cl₂ starting reagents, demonstrated in compounds 1, 2, and 3. To expand the diversity of gold-phosphine complexes, we synthesized compounds with the archetypical achiral phosphorus-donor ligand, DPPE, exemplified in 4^{61–63}, 5^{64–66}, according to previously reported protocols but with different anions, and the novel gold(III), 6. The synthetic approach for compound 1, was achieved by adding a chloroform solution of (R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline to a cold solution of AuCl(tht) in chloroform. This complex was dried and recrystallized from chloroform/ether to give a pale yellow neutral compound. The synthesis of 2 was carried out by refluxing an equimolar concentration of HAuCl₄·3H₂O and (R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline in chloroform for 1 h. After filtering through celite the reaction was purified by flash silica-gel chromatography to obtain 2 as a brick-red monocationic solid. We synthesized gold(III) analogs using the benzyolpyridine (C[^]N)-cyclometalated complex, 7, which was synthesized as previously reported⁶⁷. The chiral ((R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline) and achiral (DPPE) bisphosphine ligands were used in a ligand substitution reaction with 7 to give 3 and 6 respectively, after purification by silica-gel column chromatography. Phosphines are strong coordinating ligands which can readily displace the chlorine atoms. In the reaction that leads to complex 3, the formation of 2 in low yields is observed. This is as a result of reductive elimination promoted by the nucleophilic phosphine. It is a subject of intense investigation within our laboratory⁶⁸. Complexes 4 and 5 bearing DPPE ligands were synthesized to investigate the effect of perchlorate counter anions on cellular activity. The complexes were purified by recrystallization from acetonitrile as white cationic solids.

The complexes were characterized by ¹H, ¹³C, and ³¹P{¹H} NMR spectroscopy (Fig. S1–23), UV spectroscopy, and high resolution electrospray ionization mass spectrometry. Purity of the complexes was confirmed by elemental analysis. The ³¹P{¹H} of ((R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline and DPPE have single




Figure 1. Chemical structures of gold complexes under investigation.

resonances at -17 and -12 ppm respectively. Upon coordination with the gold center, the resonances shift downfield. For the gold(III) complexes, **3** and **6**, four or one signals in the $^{31}\text{P}\{^1\text{H}\}$ NMR were observed respectively. We attribute four signals in compound **3** to the presence of two diastereomers of the quinoxaline ligand and the one signals in compound **6**. P-coupling through a P-Au-P bridge was observed in both $^{31}\text{P}\{^1\text{H}\}$ NMR spectra. In compound **3**, J_{pp} was 0.12 ppm while in compound **6** it was 0.41 ppm. The presence or absence of the resonance structure of the P-C-C-P bridge influences J_{pp} coupling. Specifically, J_{pp} is smaller in the structure having the π electron bridge (complex **3**), and J_{pp} is relatively larger in the structure where the π bridge is nonexistent (complex **6**). The ^1H -NMR and $^{13}\text{C}\{^1\text{H}\}$ NMR of compound **3** shows signals that can be attributed to diastereomer resonances. Furthermore, 2-dimensional COSY (Fig. S11) and HSQC (Fig. S12) was performed to assign the features of complex **3**. Overall, the compounds under investigation in this report were synthesized and unambiguously characterized by spectroscopy and their purity ascertained.

Physical properties. UV-Vis spectra of representative complexes were measured in air-equilibrated pH 7.4 phosphate-buffered saline (PBS) or DMEM cell culture medium, which constitutes several reducing amino acids in high concentrations (mM range). The spectra of the complexes bearing phosphine (**1**, **2**, **4**, and **5**) and both phosphine and cyclometalated ligands (**3**, **6**, and **7**) are shown in Figs 2 and S24–29. The absorbance profile of the complexes is significantly influenced by the nature of the phosphine ligands as well as the cyclometalated ligands.

The high-energy bands observed in the UV-vis spectra, likely correspond to $\pi - \pi^*$ transitions from the ligands^{69,70} or of ligand-to-metal charge transfer (LMCT) or metal-to-ligand charge-transfer (MLCT) character, which has been well-characterized by TDDFT calculations (*vide infra*). For example, in complex **7** there are two bands <300 nm, there is a high-energy band at 245 nm and another peak at 295 nm, which may be as a result of MLCT or LMCT transition^{71–73}. There was no change in the absorbance profile of the gold(III) complex bearing cyclometalated and phosphine ligands (**3**) in PBS and minor changes in DMEM over the course of 48 h (Fig. S24–25). In contrast, the gold(I) bearing phosphine ligands experienced spectral changes in both PBS and DMEM over 48 h (Fig. S26–27). In PBS, the gold complexes show solubility and stability as shown from the absorption profiles in Fig. 2. A broad absorption band was noticeable for compound **1**, which can be attributed to possible aggregation due to the relatively planar and lipophilic character of the dinuclear complex, **1**, which can form π -stacking in aqueous solution. The representative examples offer insight into the role of cyclometalation and conjugated phosphine ligands to stabilize the gold center.

Complex **2**, representing Au(I), shows a continuous decrease in absorption peaks at 248 and 337 nm over time in PBS. In contrast, complex **3**, which is Au(III) showed no change in absorption bands. It can be deduced that the Au-P bonding in complex **2** is weakly stable in PBS compared to that of Au-P of complex **3**. This is supported by computational results, in that, while the four Au-P bonds of complex **2** are ~ 2.5 Å, the two Au-P of complex **3** show shorter bond lengths of 2.38 and 2.5 Å, respectively, indicative of stronger bonds. The stability associated with **3**, could be ascribed to both cyclometalated-Au bonding and adjacent Au-P bonds that enhance sigma-donation to the gold center. Complex **7**, which is another Au(III) display significant changes to the absorption bands in DMEM. It appears that chloride, a good leaving group, is substituted by amino acids contained in DMEM⁷⁴. On the contrary, it shows stability in PBS, this seems like PBS does not contain components to replace Cl of complex **7**. Additionally, PBS contain 10 mM of NaCl that is likely to help stabilize the complex.

Density functional theory and TD-DFT calculations. To gain theoretical insight into the gold complexes under investigation, DFT calculations were conducted. We used Gaussian 09 and the B3LYP functional was employed⁷⁵. The basis set used was SDD on Au atom, taking into consideration relativistic effects and the Pople-type 6–31 G(d,p) was used for all other atoms. The geometry of the computed complexes was compared with the solved X-ray crystal structures to ensure the validity of the computations performed. The result is summarized in Fig. S31. Briefly, we considered the atomic groups around the gold atoms. For complex **1**, two




Figure 2. UV-Vis absorption spectrum of Au(I) series, **1**, **2**, **4**, and **5** in PBS (**a**), **1** in CHCl₃ (**b**), Au(III) series, **3**, **6**, and **7** in PBS (**c**). Concentration of complexes = 50 μ M. DMSO was used for stock solution. (The final concentration of DMSO was 1% of the total solution).

independent distances between Au atom and P atom were 2.22 and 2.23 Å, and the calculated values showed minimal discrepancy, with an error of 3%. Similarly, two independent bond distances between Au and Cl were 2.28~2.29 Å, whereas the calculated values were within ~2% error. Interestingly, the bond angle of P-Au-Cl from the crystal structure of **1** was 171° and the corresponding calculated value was 171°. In the case of **2**, the distorted structure of **2** had four P-Au bonds and its distances were all ~2.39 Å, and the calculated values were ~2.5 Å. Measured angles of three kinds of P-Au-P were 87.79°, 137.50°, and 106.48°, respectively, while the calculated values were 86.13°, 132.65°, and 111.58°. Unlike **1** and **2**, compounds **4** and **5** possess dppe ligands, which also showed minimal discrepancy between the experimental and calculated bond distances or angles. For complex **4**, the two gold metal atoms had two separate P-Au-P bonds, all four P-Au bond distances were 2.31 Å and the calculated values were ~2.38 Å. The X-ray structure revealed two P-Au-P angles as 166.8° and 177.8°, with the determined calculated angles were 169.1° and 171.0°, respectively. Complex **5** had a distorted structure like **2**. The distance between the four P-Au distances were all 2.40 Å, while the calculated values was in the range of 2.35~2.36 Å, showing less than 3% error. The three P-Au-P angles were 86°, 117°, and 118°, and the calculated values were 91°, 128°, and 114°, respectively. Taken together, this shows that DFT calculations and the method employed can be considered suitable for providing accurate geometric information of gold complexes.

To corroborate peak assignments within the experimental absorption profiles and further provide insight into HOMO-LUMO transitions, we performed TD-DFT calculations.

In Fig. 3, the experimental UV-Vis spectrum for complex **6** was compared to the calculated spectrum. The oscillator strength and molecular orbital (MO) contributions obtained from the theoretical calculation is summarized in Table 1. The limitation of the method and basis sets used in the theoretical calculation as a result of the large relativistic effect of gold present some discrepancy, which is consistent with other gold systems in the literature. In the UV-Vis spectra, generally, 2–3 peaks were observed and the theoretical calculations (TD-DFT) were carried out to establish the relationship between the observed peaks and the associated electronic transition. The experimental absorption profile show a high-energy absorption peak located at approximately, 250 nm and a red-shifted shoulder band at ~275 nm. However, the calculated spectra show a high energy band at 350 nm and its related red-shifted band at 400 nm, confirming a discrepancy of about 100–150 nm from the experimental spectra. This is typical for gold systems^{76,77}. Furthermore, for complex **1**, the contribution of HOMO-2 to LUMO was the largest, corresponding to a MLCT transition. The HOMO-2 is largely localized on the gold and the neighboring Cl atoms and the LUMO on the phenyl/pyrazine of quinoxaline. A similar charge transfer is seen in HOMO-LUMO transition for compound **1** (Fig. S32). Additionally, MLCT is also seen in complexes **2** (Fig. S33) and **5** (Fig. S34). **2** has the same ligand as **1** and shows similar metastases: $\lambda = 221$ nm (HOMO to LUMO + 2) and $\lambda = 249$ nm (HOMO-1 to LUMO + 1), which are charge transfer from the gold center to both quinoxaline ligands. For $\lambda = 326$ nm, the HOMO-LUMO transition represents a similar transfer from the gold center to the




Figure 3. UV-Vis absorption spectrum of Au(III) complex, **6**, in PBS at the concentration of 50 μ M. DMSO was used for stock solution (red) and theoretical spectrum (blue) and oscillator strengths, f , from Table 1 for **6** (black).

Excitation	λ_{exp} (nm)	λ_{calc} (nm)	Oscillator strength	MO#, (Contributions ^a)	
A		414	0.0015	160 \rightarrow 162 (68) 161 \rightarrow 162 (28)	
B	268	407	0.0096	156 \rightarrow 162 (2)	LMCT
				159 \rightarrow 162 (16)	
				160 \rightarrow 162 (21)	
				161 \rightarrow 162 (58)	
C		380	0.0066	152 \rightarrow 162 (49)	
				152 \rightarrow 163 (20)	
				153 \rightarrow 162 (2)	
				153 \rightarrow 163 (11)	
				158 \rightarrow 163 (3)	
				159 \rightarrow 162 (5)	
				159 \rightarrow 163 (3)	
				160 \rightarrow 163 (9)	
D	237	364	0.1100	157 \rightarrow 162 (49)	LMCT
				159 \rightarrow 162 (73)	
				160 \rightarrow 162 (7)	
				161 \rightarrow 162 (6)	
E		358	0.0424	156 \rightarrow 162 (49)	
				157 \rightarrow 162 (24)	
				158 \rightarrow 162 (56)	
				161 \rightarrow 162 (4)	
F		353	0.0301	156 \rightarrow 162 (5)	
				157 \rightarrow 162 (50)	
				158 \rightarrow 162 (39)	

Table 1. TD-DFT Excitation Calculations for **6**. ^aValue is $2 \times (\text{coeff})^2 \times 100$.

periphery of the molecule. For complex **5**, electrons distributed around the metal migrate to neighboring phenyl groups: $\lambda = 243$ nm (HOMO to LUMO + 3) and $\lambda = 292$ nm (HOMO to LUMO). Similarly, for complex **5**, the high energy is caused by MLCT of HOMO to LUMO + 3, and the neighboring $\lambda = 292$ nm (HOMO to LUMO) by gold center to the surrounding phenyl groups of the the dppe ligand. In contrast, complexes **3**, **4**, **6** and **7** show mainly LMCT transitions. For **3**, high energy peaks ($\lambda = 256$ nm) were observed in quinoxaline-to-gold charge transfer (HOMO-3 to LUMO and HOMO to LUMO + 1) and low energy peaks were considered as transition from benzopyridine to gold center (HOMO-2 to LUMO and HOMO-1 to LUMO, Fig. S35). Complex **4** is largely due to the transition of HOMO-2 to LUMO for $\lambda = 241$ nm, from the two phenyl rings of the dppe ligand to the gold, and HOMO to LUMO for $\lambda = 294$ nm from the phenyl to gold (Fig. S36). For **6**, $\lambda = 237$ nm correspond to, HOMO-2 to LUMO, which is consistent with a LMCT transition based on the localization of the HOMO-2 and the LUMO and $\lambda = 268$ nm is as a result of a similar transition, HOMO to LUMO (Fig. 4). Complex **7** also possess a similar profile with $\lambda = 234$ nm corresponding to HOMO-2 to LUMO + 1, which is a LMCT transition, and $\lambda = 285$ nm, resulting from HOMO to LUMO with LLCT transition (Fig. S37). Although the complexes use




Figure 4. LUMO, HOMO, HOMO-1, HOMO-2, HOMO-4, and HOMO-5 electronic density maps for **6**. Calculated on B3LYP, SDD on Au and 6–31 G(d,p) on others.

similar ligands (quinoxaline, benzoylpyridine, and dppe), the type of charge transfer in the UV-Vis spectrum is different (MLCT, LMCT, or LLCT)^{69–73} because the different types of ligands, combination of ligands, and the different coordination number of the gold make a difference. The Au(III) complexes all display LMCT transitions and the Au(I) complexes display MLCT transition with the exception of **4**. Overall, the study provide insight into the MO contributions of the experimentally obtained absorption profiles of these cytotoxic compounds.

Variable temperature NMR. Prior to biological investigation of these complexes, we assessed the thermal stability of representative compounds in DMSO-*d*₆ and D₂O. Given that stock solutions of the complexes were prepared in DMSO prior to biological, photophysical, or electrochemical evaluation DMSO-*d*₆ was used. Consequently, all the biological evaluation is in aqueous base medium, thus studying their stability in D₂O was appropriate. We measured the ¹H-NMR of complexes **1–6** within a temperature range of 24–80 °C (Fig. S38–50). There were no obvious changes in the ¹H-NMR spectra for the respective complexes studied over the temperature range, indicative of stability of these complexes under harsh conditions. In summary, these gold compounds show thermal stability in DMSO and D₂O, which is an important characteristic for biologically relevant transition metal complexes.

X-ray crystallography. Single crystals of four complexes out of the six compounds studied were obtained and the crystal structures were determined by X-ray crystallography. Crystal structures with optimized structures for **1**, **2**, **4**, and **5** are shown in Fig. 5. We note that **4**^{61–63}, and **5**^{64–66} share cationic similarity to structures previously reported, for different salts of these cationic complexes. A comparison of the previously reported structures and ours reveal the perchlorate anions and no significant differences in the overall geometry of the gold complex. Moreover, the dinuclear gold compound, **4** crystallizes in the triclinic P1 space group, while **5** crystallizes in the orthorhombic space group, Pca2₁. Crystallographic information and selected interatomic distances for compounds **1**, **2**, **4**, and **5** can be found in Table S1–4. For the dinuclear complex, **1**, it crystallizes in the orthorhombic space group, P2₁2₁2₁. There is a slight distortion in the linear geometry of the P-Au-Cl bonds, for example, the P1-Au1-Cl1 angle is 171.77(9). The rigid chiral bisphosphine ligand may be the culprit for the observed distortion. Additionally, the bond angles C-P-Au were different for the methyl and tert-butyl group bonded to the phosphorus. For example, C9-P1-Au1 is 108.1(3), whereas C10-P1-Au1 is 112.6(3), indicative of a larger angle influenced by the bulkier tert-butyl fragment. Importantly, the dinuclear gold compound does not have a bond between the two gold atoms. Compound **2** crystallizes in the monoclinic, C2 space group which is a deviation from **1**, despite the similar chiral ligand environment. The complex exhibits an unusually distorted square planar geometry for Au(I) species. The Au-P bond distances for both **1** and **2** are slightly invariant as we observe a longer bond distance for Au-P in **2**, when compared to Au-P distances in **1**. For example, complex **1**, Au1-P1: 2.225(2) Å and Au2-P2: 2.236(2) Å, and for the complex **2**, Au1-P1: 2.3889(14) Å, Au1-P4: 2.390(2) Å, Au1-P2: 2.3928(19)




Figure 5. X-ray crystal and calculated structures of **1**, **2**, **4**, and **5**. Ellipsoids are drawn at 50% probability level. Hydrogen atoms bound to carbon atoms and solvent are omitted for clarity. The structures were calculated on B3LYP/SDD, 6–31 G(d,p). No imaginary frequencies were found.




Figure 6. Cyclic voltammograms recorded at a platinum electrode in DMSO solution of 1.0 mM **2**, with NaClO_4 supporting electrolyte; scan rate 0.3, 0.2, 0.1, and 0.075 V sec^{-1} .

\AA , and Au1-P3: 2.3964(15) \AA , respectively. The distorted square planar geometry of **2**, contribute to the longer Au-P bond distances than that of **1**. We note that the Au-P bonds for the structure of **4** is comparable to that of compound **2** but the Au-P bond distances for **5** are longer, averaging 2.406(8) \AA . This is consistent with the fact that distorted gold(I) complexes such as **2** and **5** exhibit slightly longer Au-P distances than their dinuclear counterparts, **1** and **4**. The cone angle of DPPE to the Au center in **5** are smaller (P1-Au1-P2 85.97(3) \AA) in comparison to the ((R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline ligand in **2** (P1-Au1-P2 87.91(5) \AA).

Electrochemistry. To elucidate the reduction and oxidation properties of these gold complexes, we measured the cyclic voltammetry in DMSO with sodium perchlorate (NaClO_4) as supporting electrolyte at a Pt electrode, using CH-600D potentiostat equipment. One reversible reduction event was observed for the gold(I) complex, **1** at a potential of -1.20 V (Fig. S52). In an oxidative sweep, an oxidation peak appears at -0.98 V. This phenomenon is observed in the free ligand, ((R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline (QuinoxP), which possess a more negative reduction potential at -1.68 V. Complex **2**, displays two successive reversible processes with reduction potentials at -1.26 V and -1.38 V respectively (Fig. 6). Note that **2** is supported by two QuinoxP ligands with distortions from a classical linear Au(I) complex that may lead to two closely distinct redox events. The result and the absence of metallic gold at the platinum working electrode led to the conclusion that the overall reduction for this class of Au(I) complexes is ligand-centered rather than metal-centered⁷⁸.

The electrochemical behavior of **4** and **5**, which are Au(I) complexes bearing DPPE ligands were investigated. Complex **4** shows irreversible reduction peak at -0.84 and -1.54 V (Fig. S53). Similarly, **5** show irreversible reduction events at -0.81 V and -1.55 V with no oxidation events (Fig. S54). The events for **4** and **5** are considered to occur on the ligand, given that the reduction potentials of compounds **4** and **5** were similar and consistent with dppe as well as the lack of gold precipitation. We attribute the observation to stability of the complexes and ligand-centered redox events. Furthermore, we studied the electrochemical behavior of the gold(III) complexes, **3** and **6** in DMSO using cyclic voltammetry. As shown in Fig. S55, irreversible reduction peak at -0.80 V was




Figure 7. UV-Vis absorption spectra of **3**, BSA, and **3** and BSA mixture in PBS. Concentration of complex **3** and BSA = 25 μ M. DMSO was used for stock solution of **3**.

observed and a reduction peak at -1.46 V for **3**. In addition, a corresponding oxidation event was observed at -1.27 . **6** showed two reversible reductions at -1.01 and -1.37 V, and the paired oxidation events at -0.86 and -1.31 V were observed, respectively (Fig. S56). Typically, gold(III) undergo two separated Au(III)/Au(I) and Au(I)/Au(0) steps in non-aqueous environment or three electron⁷⁹, Au(III)/Au(0) reduction in aqueous solutions due to disproportionation of Au(I) in aqueous solution^{80–82}. Our observation lean more towards the former with an initial Au(III)/Au(I) reduction for **3** and **6**.

Reactivity with BSA. Spectrophotometric investigations of the gold complexes (**1–6**) described in this report in a reaction with bovine serum albumin (BSA) was performed under physiological conditions. Taking advantage of the intense absorption bands of the gold complexes and BSA, we monitored the progress of the reaction using 1:1 ratio of BSA and buffered solutions of each gold complex over 24 h. Serum albumin is a major soluble protein component present in the circulatory system and has many physiological functions⁸³. Importantly, BSA acts as a carrier for various pharmacological agents. It must be noted that BSA has been extensively studied, and shares homology with human serum albumin (HSA)⁸⁴. Often, gold compounds bind methionine and cysteine residues in BSA via the sulfur atoms. The inherent absorption peaks for complexes **2–6** were minimally affected by the addition of the BSA solution over a 24 h period (Figs 7 and S57–S61). It is also worth pointing out that the peak corresponding to the absorption of BSA at 280 nm was unaffected under the experimental conditions. The ability for compound **1** to aggregate in aqueous solution limited the ability to evaluate it under the experimental conditions. However, a solution of compound **1** with BSA did not affect the peak attributed to BSA (Fig. S62). For compound **2**, while a decrease in the absorption band corresponding to MLCT at ~ 250 nm was observed, no changes in the band at 325 nm was observed in the course of the experiment. The observed decrease is consistent with the time-dependent study of **2** in PBS. Also, the peak corresponding to BSA remained unchanged throughout the 24 h period. Complexes **3** and **6** are gold(III) compounds with cyclometalated ligands but different bisphosphine ligands. Interestingly, none of the peaks associated with the complexes or BSA changed, indicative of stability in the presence of BSA over 24 h. While the shoulder peak at 300 nm disappeared in the case of complex **4** (LMCT), the BSA peak at 250 nm was unmodified. Complex **5** on the other hand did not display any alteration in its peak. In general, there was no indication of the formation of metallic gold as no brown precipitate formed in any of the reaction over the duration of the experiments. Using HPLC (Fig. S63–S64) we characterized the extent of interaction of the test compounds and BSA. This approach can be used to quantify potential binding of gold compounds with BSA by evaluating the retention times and area of peaks associated with individual agents as well as reaction solutions of test compounds and BSA. Following the UV-vis studies, we used compounds **2** and **3** for the HPLC study based on the common chiral ligands but different oxidation states. There were no changes in the peaks, indicative of no covalent modification of BSA or changes to the gold compounds. These compounds by virtue of their coordinated ligands and cyclometalation demonstrate high stability even towards proteins like BSA. Detailed studies by Minghetti and co-workers⁸⁵ on the reactivity of selected gold(III) complexes with serum albumin under similar experimental conditions showed varied stability of the gold complexes in the presence of BSA. This result has important implications for the pharmacological activity of these gold complexes, in that they can avoid premature deactivation until they reach their target and also reduce off-target effects.

Cellular toxicity studies. The antiproliferative properties of these gold complexes were evaluated in a panel of cancerous cell lines using crystal violet assay for H460 and OVCAR8. We used an ATP-dependent luminescence cell assay, cell titre glo, for K562 cells. To extend the therapeutic utility of these novel drug candidates, we performed cytotoxicity studies with normal retinal pigment epithelium, RPE-NEO. Auranofin and cisplatin were used as controls. We obtained dose-response curves from the cell viability experiments and subsequently derived IC_{50} values (concentration required to kill 50% of cells) summarized in Table 2. Complexes **1–6** displayed high nanomolar to low micromolar cell killing which are 2–10 folds better than cisplatin. None of the gold-phosphine complexes display cross-resistance evidenced by indifferent toxicities in cisplatin resistant cells, including the well-characterized high grade-serous ovarian cancer (HGSOC) cell line, OVCAR8, which demonstrate the example of high potency of these novel Au complexes in clinically relevant tumor cells. Generally, the gold compounds studied are slightly less potent toward RPE-Neo cells, indicative of selective toxicity for cancerous cells compared

Compound	IC ₅₀ (μM) K562 (leukemia)	IC ₅₀ (μM) H460 (lung)	IC ₅₀ (μM) OVCAR8 (ovarian)	IC ₅₀ (μM) RPE-NEO (normal)
1	0.92 ± 0.02	0.43 ± 0.04	0.10 ± 0.01	0.47 ± 0.01
2	0.35 ± 0.05	0.16 ± 0.02	0.83 ± 0.12	6.49 ± 0.02
3	1.74 ± 0.18	0.46 ± 0.02	0.38 ± 0.04	0.55 ± 0.02
4	0.23 ± 0.08	0.16 ± 0.03	0.79 ± 0.13	1.53 ± 0.01
5	0.45 ± 0.03	2.53 ± 0.22	0.18 ± 0.06	2.94 ± 0.01
6	1.65 ± 0.12	0.22 ± 0.01	1.09 ± 0.34	1.11 ± 0.01
auranofin	0.42 ± 0.05	0.52 ± 0.02	0.34 ± 0.06	1.09 ± 0.03
cisplatin	13.05 ± 1.02	5.63 ± 1.02	8.95 ± 0.44	12.98 ± 0.04

Table 2. IC₅₀ Values (μM) of 1–6, cisplatin, and auranofin against a panel of cancer cell lines after 72 h exposure. Cisplatin stock was prepared in PBS and gold compounds were freshly prepared in DMSO and used immediately. DMSO concentration was < 1%.

Complex	Redox potential (eV)		Lumo (eV)	Homo (eV)	IC ₅₀ (μM) K562
	Epc	Epa			
1	−1.2	−0.979	−3.18	−6.07	0.92 ± 0.02
2	−1.26, −1.38	−1.12, −1.26	−2.58	−4.24	0.35 ± 0.05
3	−0.80, −1.46	−1.27	−8.52	−12.03	1.74 ± 0.18
4	−0.84, −1.54		−6.11	−10.90	0.23 ± 0.08
5	−0.81, −1.55		−3.10	−7.76	0.45 ± 0.03
6	−0.01, 1.37	−0.86, 1.31	−8.13	−11.90	1.65 ± 0.12

Table 3. Electrochemical potentials, LUMO/HOMO energies, and cytotoxicity of the gold complex 1–6.




Figure 8. Whole cell (OVCAR8) uptake results from auranofin (5 μM) and complexes 1–6 (5 μM). Cells were incubated with compounds for 15 h.

to healthy cells. Compounds 2 display ~8–40-fold higher potency in cancer cells than the normal RPE-Neo cell line.

Table 3 summarizes the electrochemical potentials, LUMO eigenvalues and representative cytotoxicity of the gold complexes studied in this report. In general, the redox active behavior of the complexes may be suggestive of redox induced cell-death. However, we could not establish a positive correlation between reduction potentials, LUMO eigenvalues and cytotoxicity. Several factors affect the induction of cell death by metal-based drugs and such correlations must be cautiously applied.

Cellular uptake studies. To gain insight into the intracellular behavior of the gold reagents, we studied the whole cell uptake of 1–6 and auranofin as well as subcellular distribution of Au for 1 and 3. OVCAR8 cells were incubated with the gold compounds (5 μM) for 15 h. The Au content was measured by using ICP-OES, calibrated with HAuCl₄ standard. Differential whole cell uptake was observed for all compounds with neutral complexes, auranofin and 1 displaying the highest uptake respectively and 6 taken up the least (Fig. 8). Generally, increased cellular uptake correlates well with high cytotoxicity and biological effects thereof. Previous work using other gold phosphine complexes show that increased uptake is accompanied by cell growth inhibition, and that a parabolic




Figure 9. FITC Annexin V/PI apoptosis dead cell assay. OVCAR8 cells were used. Plots of untreated cells (negative control), cells treated with **1** ($2\ \mu\text{M}$ for 48 h), **3** ($2\ \mu\text{M}$ for 48 h), auranofin ($2\ \mu\text{M}$ for 48 h), or cisplatin ($2\ \mu\text{M}$ for 48 h).

dependence between cell growth inhibition, uptake, and lipophilicity does exist^{86,87}. Thus, it is possible to predict whether changes in the oxidation number of gold complexes and changes in lipophilicity of the complexes would have an effect on uptake and growth inhibition. However, the set of test compounds investigated in this report did not establish significant correlations of uptake and cytotoxicity. A clear observation of the data revealed higher uptake for dinuclear complexes (**1** or **4**) over mononuclear gold complexes bearing chiral or achiral phosphine ligands respectively. It is likely that the dinuclear gold increases lipophilicity of the agents. Additionally, the use of chiral QuinoxP ligands have a higher lipophilic character over the dppe ligands. We evaluated **1** and **3**, which bear the same chiral ligand but different oxidation states in a series of biological experiments and although IC_{50} values do not show significant differences, apoptosis assay (vide infra) reveal a much higher early to late-stage apoptosis for **1**, which has a higher cellular uptake than **3**. Following the incubation of OVCAR8 cells with **1** or **3**, we isolated the nuclear component from the cytoplasm and the residual cell pellet. As shown in Fig. S65, complex **1** or **3** was localized predominantly to the cytoplasmic fraction at $200\ \text{pmol}/10^6$ cells concentration. In contrast, a lower localization within the nuclear fraction at $15\ \text{pmol}/10^6$ cells was observed for both **1** and **3**. The similar Au concentration in the subcellular fractions despite the different structural scaffolds may be the clue to the similar growth inhibition observed. The concentration found within the cell residue (pellet) was similar to that of the nuclear fraction, within margin of error. These results demonstrate that the new Au constructs largely localize and may target cytoplasmic proteins owing to their lipophilic chiral ligands with minimal potential to target genomic DNA.

Mode of action studies. To further understand the cellular responses evoked by **1** or **3**, the compounds were examined for apoptotic effects. Mitochondria dysfunction and ER stress can result in apoptosis. Characteristically, cells undergoing apoptosis have associated cell membrane disorientation. This leads to efficient phosphatidylserine residue translocation from the interior of the cell to the exterior membrane, which can be readily detected by Annexin V molecules. We performed a dual-stain experiment involving FITC-labeled Annexin V and propidium iodide (PI) for flow cytometry analysis. The HGSOc cell line, OVCAR8, were treated with **1**, **3**, auranofin or cisplatin for 72 h. We observed a large population occurring as late-stage apoptotic cells for the Au(I) compounds, i.e. **1** and auranofin. In general, all the Au complexes induce significant apoptosis over cisplatin as shown in Fig. 9. Taken together, these Au reagents display enhanced *in vitro* potency when compared with the conventional platinum(II)-based agent, cisplatin.

Suspicious of mitochondria dysfunction and ROS production as primary inducers of cell death, we conducted intracellular reactive oxygen species (ROS) experiments using human cancer cell line, OVCAR8 (Fig. 10b). Mitochondria are the power hub that control cell death signaling within cells and generate large amounts of ROS within the cell. That said, the mitochondria is also susceptible to ROS attack. Thus, measuring ROS production induced by the gold compounds presented in this report is rational. Under the experimental condition, compound treated cells revealed a low amount of ROS. It is fair to say that all compounds inhibit ROS, especially the




Figure 10. (a) Histogram representing the different phases of the cell cycle of OVCAR8 in the presence or absence **1** (2 μ M) over the course of 72 h. 24 h treated with **1**: G1: 42.22%, S: 36.39%, G2/M: 21.38%, 48 h treated with **1**: G1: 47.27%, S: 34.46%, G2/M: 18.26%, 72 h treated with **1**: G1: 54.99%, S: 29.48%, G2/M: 15.53%. (b) Intracellular ROS using OVCAR8 cells and dihydrorhodamine 123 as dye. Plots show untreated cells (negative control), H₂O₂ treated cells (positive control), and cells treated with **1**–**7** (5 μ M, overnight) or auranofin (5 μ M, overnight). (c) Histogram plot of the effects of **1** and **2** (μ M) on mitochondrial membrane potential using rhodamine 123 in OVCAR8 cells. (d) immunoblotting for the expression of apoptosis and DNA damage response proteins in OVCAR8 cells following incubation with **1**, **2**, or **3**. (full-length blots/gels are presented in Supplementary Fig. 68).

Au(III) reagent, **3**, as measured by the fluorescence of dihydrorhodamine 123 using flow cytometry. Together, the study suggests the ability of these gold complexes to modulate intracellular ROS.

Having established the effects of **1**–**6** on intracellular ROS, mitochondrial membrane potential studies were conducted to monitor mitochondrial insults. Notably, **1** and **2**, largely depolarized the mitochondria membrane by measuring the fluorescence of rhodamine 123 using flow cytometry (Figs 10c, S66). Well studied organic small-molecule that modulate ROS are known to induce mitochondrial membrane potential depolarization resulting in cell death⁸⁸. Additionally, a few organometallic gold complexes induce mitochondria depolarization as a result of mitochondrial dysfunction or ER stress^{1,89}. Mitochondria membrane depolarization often stimulates caspase signaling, hence, using immunoblotting analyses, we monitored changes in the expression of biomarkers related to apoptosis and DNA damage response (Fig. 10d). OVCAR8 cells incubated with **1**–**3** for 48 h revealed marked increase in caspase 3 and 9 levels^{2,41,42,90}. While **3** induced differential expression of cleaved PARP and γ -H2AX, compounds **1** and **2** did not, suggesting that **3** may impose a broader mechanism of action. The generation of ROS is capable of compromising mitochondria function, leading to the activation of caspase-3 and cleavage of PARP. Our experimental results parallel the existing mode of action with a unique differentiation. For example, complexes **1** and **2** are not involved in ROS production and do not induce PARP cleavage. This suggests that within the apoptotic program, **1** and **2** may cause late apoptosis as rightly observed for **1** (Fig. 9) since PARP cleavage occurs early during apoptosis in order to avoid energy (NAD and ATP) depletion needed for later stages in the apoptotic program^{91,92}. Overall, these studies confirm the differentiated mechanism of novel chiral or non-chiral gold complexes that are capable of inhibiting ROS in cells, setting off mitochondrial membrane potential depolarization as a result of perturbed redox homeostasis that lead to apoptosis in cancer cells. The preliminary mechanistic activity of the gold candidates was characterized in OVCAR8 cells by assessing cell cycle effects. Using flow cytometric analyses on OVCAR8 cells after treatment with **1** or **3**, incubating the cells with each agent at ~two-fold higher concentrations than their respective *in vitro* IC50 values for either 24, 48 or 72 h. The study revealed that **1** and **3** stalled the cell cycle at the G0/G1 phase in a time-dependent manner. Notably, within 24 h, there was an increase in the G2/M phases, which diminished to levels relative to untreated controls by 72 h (Figs 10a and S67). This observation differs from cell cycle patterns of cisplatin-treated cells, which primarily induce G2/M phase arrest by 72 h for most ovarian cancer cells. Undoubtedly, a more rigorous biological characterization is required to fully elucidate the mechanism.

Conclusion

The synthesis and characterization, electrochemical, and biological evaluation of six gold complexes bearing chiral and achiral bisphosphine ligands were investigated. All compounds display potent cytotoxic effects in cancer cells over normal cells. Particularly, the gold compounds described show high antiproliferative activity in a panel of cell lines including the clinically relevant HGSOE OVCAR8 cell line, ranging from 2–10-fold lower

IC₅₀ values when compared to cisplatin. The complexes investigated offer a broader mechanism of action than cisplatin or auranofin including apoptosis, mitochondria depolarization and G0/G1 cell cycle arrest. Despite differential intracellular accumulation of complexes **1–6**, the cytotoxic effects were not significantly invariant. The redox potential of these complexes is affected by the choice of ligands. Additionally, theoretical insight using DFT and TD-DFT calculations demonstrated HOMO-LUMO orbital distributions which can inform future design and donor effect of ligands for stability and prediction of excited states. Although this study uses a relatively modest set of compounds, they represent an important proof-of-concept study for the development of new gold-phosphine complexes that possess ligand variability and different oxidation states. Ongoing studies are being performed to expand the scope of stable gold(III)-phosphine complexes as effective anticancer agents.

Methods

General information. Auranofin and Cisplatin were purchased from Santa Cruz Biotechnology Inc. and Strem, respectively and used without further purification. All other reagents were purchased from Strem, Sigma Aldrich, or Alfa Aesar and used without further purification. All reactions were carried out under normal atmospheric conditions. Deuterated solvents were purchased from Cambridge Isotope Laboratories (Andover, MA). ¹H, ¹³C, ³¹P, COSY, and HSQC NMR spectra were recorded on a Varian Unity 400/500 NMR spectrometer with a Spectro Spin superconducting magnet in the University of Kentucky NMR facility. Chemical shifts in ¹H, ¹³C, COSY, and HSQC NMR spectra were internally referenced to solvent signals (¹H NMR: DMSO at δ = 2.50 ppm; ¹³C NMR: DMSO at δ = 39.52 ppm), and those in ³¹P NMR spectra were externally referenced to 85% H₃PO₄ in D₂O (δ = 0 ppm). Electrospray ionization mass spectrometry (ESI-MS) was performed on an Agilent Technologies 1100 series liquid chromatography/MS instrument. High-resolution mass spectra (HRMS) were obtained by direct flow injection (injection volume = 5 or 2 μL) ElectroSpray Ionization (ESI) on a Waters Qtof API US instrument in the positive mode (CIC, Boston University). Typical conditions are as follows: capillary = 3000 kV, cone = 35 or 15, source temperature = 120 °C, and desolvation temperature = 350 °C. In addition to spectroscopic characterization, bulk purity of all new compounds was assessed by combustion elemental analysis for C, H, N. Elemental analysis was carried out at the microanalysis lab at University of Illinois Urbana Champaign using Perkin Elmer 2440, Series II with a combustion temperature of ~2000 °C and accuracy of 0.3% abs. Reactions were monitored using aluminum backed silica-gel thin-layer chromatography (TLC) plates (Silicycle, TLA-R10011B-323, Canada) and visualized under low-wavelength light (254 nm) or stained with iodine on silica for visualization with the naked eye. Purification of reactions was performed using silica-gel (Silicycle, P/N: R10030B (SiliaFlash® F60, Size: 40–63 μm, Canada) chromatography. The CombiFlash® Rf + Lumen, Teledyne ISCO was used for purification of some compounds. Quantification of elemental gold in samples was performed using ICP-OES at the University of Kentucky Energy Research and Training Laboratory. Flow cytometry experiments were performed at the University of Kentucky flow cytometry core facility. Quantum chemical calculations using Gaussian was performed on the University of Kentucky high performance computing (HPC) facility.

[2,3-bis(tert-butylmethylphosphino)quinoxaline]digold(I) (1) Under normal atmospheric conditions, in a 10 mL scintillation vial was placed (R,R)-(-)-2,3-bis(t-butylmethylphosphino)quinoxaline (15.5 mg, 0.05 mmol). Chloroform (2 mL) was added and the solution (golden) was stirred at room temperature. To the solution was added solid white Au(tht)Cl (15.0 mg, 0.05 mmol). The solution turned brick red instantly. The solution was stirred for about 15 min and monitored by TLC in 100% chloroform. The solution was passed through celite and solvent allowed to evaporate under vacuum. The residue was washed with diethyl ether and filtered. The solid was dried in vacuo to obtain a light purple solid. Yield: 21 mg, 57.1%. ¹H NMR (400 MHz, chloroform-d) δ 8.21 (dd, J = 6.4, 3.5 Hz, 1 H), 8.01 (dd, J = 6.5, 3.5 Hz, 1 H), 2.19 (d, J = 8.0 Hz, 3 H), 1.43 (d, J = 17.1 Hz, 9 H). ¹³C NMR (101 MHz, chloroform-d) δ 153.36, 153.16, 152.96, 152.74, 152.53, 140.13, 140.09, 140.05, 133.55, 129.39, 35.93, 35.89, 35.74, 35.73, 35.57, 35.53, 28.06, 28.02, 28.00, 11.98, 11.96, 11.79, 11.75, 11.58, 11.56. ³¹P NMR (162 MHz, chloroform-d) δ 29.02. HRMS (ESI) (m/z): calcd. for C₁₈H₂₈Au₂Cl₂N₂P₂ [M + Na] 821.0334, found: 821.0362. Anal. Calcd. for C₁₈H₂₈Au₂Cl₂N₂P₂: C, 27.05; H, 3.53; N, 3.51. Found: C, 27.13; H, 3.77; N, 3.89.

Bis-[2,3-bis(tert-butylmethylphosphino)quinoxaline]gold(I) chloride (2) Under normal atmospheric conditions, in a 25 mL round bottom flask was placed (R,R)-(-)-2,3-bis(t-butylmethylphosphino)quinoxaline (39.0 mg, 0.117 mmol). Chloroform (6.0 mL) was added and the solution (golden) was stirred at room temperature. To the solution was added solid white Au(tht)Cl (37.0 mg, 0.115 mmol). The solution turned brick red instantly. The solution was stirred for about 15 min and monitored by TLC in 5% MeOH in DCM. A purple precipitate was obtained. Yield: 26 mg, 23.0%. ¹H NMR (400 MHz, chloroform-d) δ 8.25 (dd, J = 6.4, 3.5 Hz, 1 H), 7.99 (dd, J = 6.5, 3.4 Hz, 1 H), 2.01 (s, 3 H), 1.28 (s, 9 H). ³¹P NMR (162 MHz, chloroform-d) δ 13.05. HRMS (ESI) (m/z): calcd. for C₃₆H₅₆AuN₄P₄ [M-Cl]⁺ 865.3121, found: 865.3104. Anal. Calcd. for C₃₆H₅₆AuClN₄P₄·0.3CH₂Cl₂: C, 47.05; H, 6.16; N, 6.05. Found: C, 47.18; H, 6.27; N, 5.90.

(2-benzoylpyridine)[(2,3-tert-butylmethylphosphino)quinoxaline]gold(III) dichloride (3) Under normal atmospheric conditions, cyclometalated Au(III)Cl₂ (26.1 mg, 0.058 mmol) was placed in a 25 mL round bottom flask and 5 mL of chloroform was added, the solution turned white. (R,R)-(-)-2,3-bis(t-butylmethylphosphino)quinoxaline (19.8 mg, 0.059 mmol) was added, the solution turned golden peach color. The solution was stirred for about 2 hours. The solution was monitored by TLC in 5% MeOH in DCM and Au starting materials disappeared. The product was separated by flash silica-gel chromatography with 5% MeOH in DCM as eluent. A bright purple precipitate was obtained. Yield: 35.8 mg, 73.6%. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80–8.75 (m, 1 H), 8.48 (dd, J = 11.7, 5.7 Hz, 1 H), 8.40–8.20 (m, 3 H), 8.18–8.01 (m, 1 H), 8.01–7.92 (m, 2 H), 7.92–7.83 (m, 1 H), 7.76–7.62 (m, 2 H), 7.41 (q, J = 7.5 Hz, 1 H), 2.68 (d, J = 12.7 Hz, 1 H), 2.47 (s, 2 H), 2.38 (d, J = 11.9 Hz, 1 H), 2.02 (d, J = 12.6 Hz, 2 H), 1.48–1.36 (m, 9 H), 1.15–1.05 (m, 9 H). ¹³C NMR (101 MHz, DMSO-d₆) δ 198.15, 198.11, 157.15, 155.89, 155.29, 150.28, 149.66, 149.49, 149.00, 148.81, 148.72, 141.97, 141.90, 139.66, 139.6, 137.92, 137.89, 137.37, 136.95, 136.88, 135.37, 135.27, 135.14, 135.02, 134.54, 134.45, 134.18, 129.98, 126.79, 126.52,

126.34, 126.04, 124.58, 124.47, 54.92, 37.91, 37.68, 36.97, 36.73, 27.11, 27.09, 26.53, 26.51, 26.48, 26.45, 25.34, 25.32, 6.43, 6.10, 5.62, 5.01, 4.66, 4.37. ^{31}P NMR (162 MHz, CDCl_3) δ 50.35 (d, $J = 20.1$ Hz), 49.39 (d, $J = 19.7$ Hz), 43.82 (d, $J = 19.7$ Hz), 37.83 (d, $J = 19.8$ Hz). HRMS (ESI) (m/z): calcd. for $\text{C}_{30}\text{H}_{36}\text{AuClN}_3\text{OP}_2$ [M-Cl] $^+$ 748.1688, found: 748.1685. Anal. Calcd. for $\text{C}_{30}\text{H}_{36}\text{AuCl}_2\text{N}_3\text{OP}_2 \cdot 0.5\text{CH}_2\text{Cl}_2 \cdot 0.8(\text{CH}_3\text{CH}_2)_2\text{O}$: C, 45.67; H, 5.12; N, 4.74. Found: C, 46.03; H, 4.96; N, 4.40.

Bis[μ -[1,2-ethanediylbis(diphenylphosphine- κ P)]]digold(I) diperchlorate (4) Under normal atmospheric conditions, $\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$ (200.0 mg, 0.508 mmol), 1,2-Bis(diphenylphosphino)ethane, DPPE, (424.0 mg, 1.064 mmol), and NaClO_4 (186.0 mg, 1.519 mmol) were placed in a 100 mL round bottom flask and 40 mL of MeCN was added. The reaction solution was stirred and refluxed overnight. And then it was filtered and the solvent was allowed to evaporate under vacuum. A white precipitate was obtained. Yield: 146.8 mg, 20.8%. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.80–7.09 (m, 5H), 2.55 (s, 1H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 133.22, 132.03, 130.34, 129.33, 128.85. ^{31}P NMR (162 MHz, $\text{DMSO-}d_6$) δ 21.23. HRMS (ESI) (m/z): calcd. for $\text{C}_{52}\text{H}_{48}\text{Au}_2\text{ClO}_4\text{P}_4$ [M-ClO_4] $^+$ 1289.1523, found: 1289.1545.

Bis[1,2-ethanediylbis(diphenylphosphine- κ P)]gold(I) perchlorate (5) Under normal atmospheric conditions, $\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$ (200.0 mg, 0.508 mmol), 1,2-Bis(diphenylphosphino)ethane, DPPE, (424.0 mg, 1.064 mmol), and NaClO_4 (186.0 mg, 1.519 mmol) were placed in a 100 mL round bottom flask and 40 mL of MeCN was added. The reaction solution was stirred at room temperature overnight. And then it was filtered and the solvent was allowed to evaporate under vacuum. A white precipitate was obtained. Yield: 230 mg, 41.4%. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.88–7.11 (m, 5H), 2.55 (s, 1H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 133.25, 132.03, 130.34, 128.85, 27.55. ^{31}P NMR (162 MHz, $\text{DMSO-}d_6$) δ 21.24. HRMS (ESI) (m/z): calcd. for $\text{C}_{52}\text{H}_{48}\text{AuP}_4$ [M-ClO_4] $^+$ 933.2372, found: 933.2385.

(2-benzoylpyridine)[1,2-ethanediylbis(diphenylphosphine)]gold(III) dichloride (6) Under normal atmospheric conditions, cyclometalated Au(III)Cl_2 (26.8 mg, 0.060 mmol) was placed in a 25 mL round bottom flask and 5 mL of chloroform was added. 1,2-Bis(diphenylphosphino)ethane, DPPE, (23.7 mg, 0.059 mmol) was added and the reaction solution was refluxed for 4 hours. The reaction was monitored by TLC in 5% MeOH in DCM, the target compound showed an $R_f \sim 0.3$. After TLC. The product was separated by flash silica-gel chromatography with 5% MeOH in DCM as eluent. Yield: 19.4 mg, 38.9%. ^1H NMR (400 MHz, Chloroform- d) δ 8.59 (d, $J = 4.7$ Hz, 1H), 8.22–8.06 (m, 2H), 7.95 (m, $J = 15.3$, 5.9 Hz, 6H), 7.83–7.73 (m, 5H), 7.72–7.34 (m, 14H), 3.79 (s, 2H), 3.18 (s, 2H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 193.98, 151.88, 148.73, 141.73 (d, $J = 6.4$ Hz), 137.60 (d, $J = 16.4$ Hz), 134.32, 133.47–132.48 (m), 131.54, 129.69, 129.11, 127.99, 124.55, 120.11, 119.24, 117.95, 117.10, 79.20, 24.49, 22.09. ^{31}P NMR (162 MHz, $\text{DMSO-}d_6$) δ 27.87, 27.46. HRMS (ESI) (m/z): calcd. for $\text{C}_{38}\text{H}_{32}\text{AuCl}_2\text{NOP}_2$ [M-Cl] $^+$ 812.1313, found: 812.1315. Anal. Calcd. for $\text{C}_{38}\text{H}_{32}\text{AuCl}_2\text{NOP}_2$: C, 53.79; H, 3.80; N, 1.65. Found: C, 53.51; H, 3.90; N, 1.46.

Dichloro(2-benzoylpyridine)gold(III) (7) This procedure was adapted from previous reports in the literature^{93–95}. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 9.48 (d, $J = 5.8$ Hz, 1H), 8.56 (t, $J = 7.7$ Hz, 1H), 8.37 (d, $J = 7.7$ Hz, 1H), 8.14–8.05 (m, 1H), 7.76 (d, $J = 7.6$ Hz, 1H), 7.73–7.65 (m, 1H), 7.48 (m, 7.51–7.45, 2H). LRMS (ESI, positive mode): calcd. for $\text{C}_{12}\text{H}_8\text{AuCl}_2\text{NO}$ [M^+] 448.96, found: 449.00.

UV-Vis spectrophotometric measurements. Stock solutions (1 mM) of complexes **1–7** were prepared in DMSO. For studies with PBS and DMEM, the gold solutions were diluted with the respective diluent (PBS or DMEM) to achieve a final gold concentration of 25 μM or 50 μM . Background scans were performed with the corresponding DMSO or solvent mixture. For the reactivity experiment with BSA, the sample solution was prepared by the above-mentioned method, and BSA was separately dissolved in PBS to prepare 1 mM stock solution and diluted with PBS. The sample solution was mixed with the BSA solution immediately before the measurement. Single scan or time-based scanning was performed as needed. The UV-Vis spectrometer used was a Shimadzu UV-1280 model.

Electrochemistry. Cyclic voltammetry was performed in dimethyl sulfoxide (DMSO) with NaClO_4 , which were purchased (Aldrich, USA) and used without further purification. All complexes (**1–6**) were dissolved in DMSO in the concentration of 1.0 mM, followed by addition of 0.01 M NaClO_4 as a supporting electrolyte. Electrochemical measurements were performed at ambient temperature using CH-600D potentiostat (CH Instruments, USA) for cyclic voltammetry. The voltammetric measurements were performed in a three-electrode cell containing a platinum working electrode, a non-aqueous Ag/AgCl reference electrode and a platinum wire as counter electrode.

Cell viability assay. Various established human ovarian, leukemia and lung cancer cell lines were seeded in 96-well plates (2×10^3 cells/well) and were incubated with RPMI 1640 supplemented with 10% FBS (150 μL) for 24 h and at 37 $^\circ\text{C}$. They were then treated with cisplatin, auranofin, or **1–6** at increasing concentrations for 72 h from stock solutions following serial dilutions. Cisplatin stock solution was prepared using PBS and the gold compounds were prepared in DMSO. Thereafter, cellular viability was assessed via the established crystal violet colorimetric assay. In brief, crystal violet reagent (50 μL of a 0.5% solution in glutaraldehyde) was added to each well and allowed to incubate with cells for 30 min. The plates were washed with water by running them under a gentle flow of tap water. The plates were air dried and dissolved with methanol (100 μL /well) and the plates were rocked for an additional 10 min. Measurements of absorbance were subsequently performed using a Genios plate reader at 570 nm (peak absorbance). All experiments were conducted in triplicate. For K562 cells, a cell density of 4,000 cells/well was used and cellular viability was assessed after treatment, using the established luminescent cell titre gloy assay.

Whole cell uptake studies. OVCAR8 cells (1×10^6) were seeded in a 6-well plate and incubated for 15 h at 37 °C. Cells were then incubated with the test compounds (5 μ M) in fresh RPMI 1640 medium (10 mL) and subsequently incubated for a given period of time (~24 h) at 37 °C. The medium was then removed and cells were collected via trypsinization. Cells were then washed with PBS (1 mL \times 3). The cells were digested by adding 0.5 mL of concentrated HCl and briefly placing them on an agitator. Cells were then transferred to a new tube containing 4.5 mL of DI water. The gold content was analyzed by ICP-OES to obtain the whole cell uptake after quantification.

Intracellular distribution. To measure the intracellular cellular uptake, ~1 million OVCAR8 cells were treated with 5 μ M compounds **1**, or **3** at 37 °C for ~17 h. The media were removed, and the cells were washed with PBS solution (1 mL \times 3), harvested, and centrifuged. The cell pellet was suspended in an appropriate volume of PBS to obtain a homogeneous suspension (100 μ L). The nuclear and cytoplasmic extraction kit (NE-PER, Thermo Scientific Inc.) was used to extract the separate cytoplasmic, nuclear, and pelleted fractions. The fractions were mineralized with 70% HNO₃ and then heated at 95 °C for 10 min. The gold content was analyzed by ICP-OES. Cellular gold levels were expressed as pmol of Au per million cells. Results are presented as the mean of three determinations for each data points.

Cell cycle analysis. OVCAR8 cells were seeded in 6-well plates (2×10^5 cells/well) and were treated with PBS, **1**, or **3** for 24 or 48 h at a concentration of 2 μ M. The cells were re-suspended in ice-cold PBS, fixed with 70% ethanol in PBS at 4 °C overnight, subsequently washed with ice-cold PBS (x2), and then incubated with RNase A (1 μ g/mL) for 20 min at 37 °C. They were then stained with PI (10 μ g/mL for 30 min in the dark) and their DNA content and cell cycle distribution were measured, using a FACSCalibur flow cytometry (BD Biosciences, USA) and as determined with ModFit software.

Apoptosis study. OVCAR8 cells were seeded in 6-well plates (5×10^5 cells/well), treated with PBS, cisplatin, auranofin, **1** or **3** at a fixed Au concentration (2 μ M) for 48 h, and harvested by trypsinization. The Annexin V-FITC Apoptosis Detection Kit (BD Biosciences) was used to determine the fraction of cells (from a total of 1×10^4 cells) that underwent apoptosis, using fluorescence-activated cell-sorting sorting (BD Biosciences, USA) and by following the manufacturer's protocol. Data were analyzed using FlowJo software.

Mitochondria membrane potential. OVCAR8 cells (175,000 cells/well) were plated in 6-well plates taking into account respective controls (untreated and unstained, untreated and stained) and test compounds. After overnight incubation of cells at 37 °C and 5% CO₂, 5 μ M of complexes was added to the desired wells and incubated overnight. We collected cells via trypsinization and centrifugation, and re-suspended cells in a solution of 70% ethanol in PBS and placed in freezer for at least 5 minutes. Rhodamine-123 solution (1 mg/ml in ethanol) was dissolved and diluted with PBS to a final concentration of 0.005 mg/mL. The solution was added (0.5 mL) to the cells re-suspended, and incubated for 30 min. Cells were pelleted by centrifugation, washed with 1 mL of PBS, and re-suspended in 0.5 mL of PBS for flow cytometry analysis.

Western blot. OVCAR8 cells (500,000 cells/well) were plated on a 6-well plates. The cells were then treated with 5 μ M gold compounds and incubated for 24 h and 48 h at 37 °C, after which media was removed and cells were washed with PBS. The cells were scraped into SDS-PAGE loading buffer (64 mM Tris-HCl (pH 6.8)/9.6% glycerol/2% SDS/5% β -mercaptoethanol/0.01% bromophenol blue) and incubated at 95 °C on a heat block for 10 min. The samples were cooled and stored at -20 °C until ready for use. Whole cell lysates were resolved by 4–20% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE; 200 V for 25 min) followed by electro transfer to a polyvinylidene difluoride membrane, PVDF (350 mA for 1 h). Membranes were blocked using 5% (w/v) bovine serum albumin (BSA) in PBST (PBS/0.1% Tween 20) and incubated with specific primary antibodies (Cell Signaling Technology and Santa Cruz Biotechnology) overnight at 4 °C. On the following day, after washing with PBST (3 \times 5 mL), the membrane was incubated with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology) in fresh BSA blocking solution. Immune complexes were detected with the ECL detection reagent (BioRad) and analyzed using a BioRad imager fitted with a chemiluminescence filter. Intracellular ROS using murine polymorphonuclear neutrophils.

X-ray crystallography. Crystals of **1**, **2**, **4**, and **5** were grown at room temperature by vapor diffusion of diethyl ether into a DMF or DCM solutions of each complex. Suitable crystals were selected by microscopic examination through crossed polarizers, mounted on a fine glass fibre in polyisobutane oil, and cooled to 90 K under a stream of nitrogen. A Bruker D8 Venture diffractometer with graded-multilayer focused MoK α X-rays ($\lambda = 0.71073$ Å) was used to collect the diffraction data from the crystal. The raw data were integrated, scaled, merged and corrected for Lorentz-polarization effects using the APEX3 package^{96–98}. Space group determination and structure solution and refinement were carried out with SHELXT and SHELXL^{99,100}, respectively. All non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms were placed at calculated positions and refined using a riding model with their isotropic displacement parameters (U_{iso}) set to either $1.2U_{iso}$ or $1.5U_{iso}$ of the atom to which they were attached. The structures, deposited in the Cambridge Structural Database, were checked for missed higher symmetry, twinning, and overall quality with PLATON¹⁰¹, an R-tensor¹⁰², and finally validated using CheckCIF¹⁰¹. See Tables S1–S8 for structure details. Of note is the different counter anions (ClO₄⁻) for **4** and **5**, which make them crystallographically distinct from similar published structures.

Cell lines and cell culture conditions. All ovarian cancer cells (OVCAR8), lung cancer cells (H460), and the leukemia cell line (K562) were maintained in the Roswell Park Memorial Institute (RPMI) 1640 medium.

With the exception of H460 which was supplemented with 15% heat inactivated fetal bovine serum (FBS) and 10% glutamine, all other cell lines were cultured in RPMI supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were grown at 310 K in a humidified atmosphere containing 5% CO₂.

Quantum chemical calculations. All calculations were performed using the Gaussian 09 package⁷⁵. Density functional theory (DFT) and time dependent density functional theory TD-DFT with Becke's three-parameter hybrid functional with the correlation functional of Lee, Yang, and Parr (B3LYP)¹⁰³ was used to calculate the equilibrium geometries and vibrational frequencies of **1**–**6**. Stuttgart-Dresden effective-core-potential basis set (SDD) for Au and 6–31 G(d,p) for C, H, N, O, P, and Cl were employed for these calculations. A vibrational analysis was accomplished to identify the nature of each optimized stationary points no imaginary frequencies were found. Optimized XYZ coordinates for all calculated molecules are attached on Table S9.

Associated Content

Supporting Information is available free of charge on the Nature Publications website. Experimental details, characterization of compounds **1**–**7**, and data regarding all X-ray crystallography, molecular biology. Crystal structures of **1** (CCDC 1817925), **2** (CCDC 1817924), **4** (CCDC 1852670), and **5** (CCDC 1852671) have been deposited at the Cambridge Crystallographic Data Centre.

References

- Huang, K.-B. *et al.* Organometallic Gold(III) Complexes Similar to Tetrahydroisoquinoline Induce ER-Stress-Mediated Apoptosis and Pro-Death Autophagy in A549 Cancer Cells. *J. Med. Chem.* **61**, 3478–3490, <https://doi.org/10.1021/acs.jmedchem.7b01694> (2018).
- Rackham, O., Nichols, S. J., Leedman, P. J., Berners-Price, S. J. & Filipovska, A. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: Implications for anticancer therapeutics targeted to mitochondria. *Biochem. Pharmacol.* **74**, 992–1002, <https://doi.org/10.1016/j.bcp.2007.07.022> (2007).
- Nobili, S. *et al.* Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. *Med. Res. Rev.* **30**, 550–580, <https://doi.org/10.1002/med.20168> (2009).
- Bertrand, B. & Casini, A. A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds. *Dalton Trans.* **43**, 4209–4219, <https://doi.org/10.1039/C3DT52524D> (2014).
- Berners-Price, S. J. *et al.* *In Vivo* Antitumor Activity and *In Vitro* Cytotoxic Properties of Bis[1,2-bis(diphenylphosphino)ethane] gold(I) Chloride. *Cancer Res.* **46**, 5486 (1986).
- Huang, H. *et al.* Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects *in vitro* and *in vivo*. *Oncotarget* **7**, 2796–2808, <https://doi.org/10.18632/oncotarget.6425> (2016).
- Zou, T. *et al.* Deubiquitinases as Anticancer Targets of Gold Complexes. *Isr. J. Chem.* **56**, 825–833, <https://doi.org/10.1002/ijch.201600044> (2016).
- Zhang, J.-J., Ng, K.-M., Lok, C.-N., Sun, R. W.-Y. & Che, C.-M. Deubiquitinases as potential anti-cancer targets for gold(III) complexes. *Chem. Comm.* **49**, 5153–5155, <https://doi.org/10.1039/C3CC41766B> (2013).
- Milacic, V. & Dou, Q. P. The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. *Coord. Chem. Rev.* **253**, 1649–1660, <https://doi.org/10.1016/j.ccr.2009.01.032> (2009).
- Pricker, S. P. Medical uses of gold compounds: Past, present and future. *Gold Bull.* **29**, 53–60, <https://doi.org/10.1007/BF03215464> (1996).
- Elsome, A. M., Hamilton-Miller, J. M., Brumfitt, W. & Noble, W. C. Antimicrobial activities *in vitro* and *in vivo* of transition element complexes containing gold (I) and osmium (VI). *J. Antimicrob. Chemother.* **37**, 911–918 (1996).
- Zou, T., Lum, C. T., Lok, C. N., Zhang, J. J. & Che, C. M. Chemical biology of anticancer gold(III) and gold(I) complexes. *Chem. Soc. Rev.* **44**, 8786–8801, <https://doi.org/10.1039/c5cs00132c> (2015).
- Berners-Price, S. J. S. P. J. In *Structure and Bonding* **70** 1–76 (Springer-Verlag, 1988).
- Chung, C. Y.-S. *et al.* A multi-functional PEGylated gold(III) compound: potent anti-cancer properties and self-assembly into nanostructures for drug co-delivery. *Chem. Sci.* **8**, 1942–1953, <https://doi.org/10.1039/C6SC03210A> (2017).
- Fung Sin, K. *et al.* Cyclometalated Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands Engage Multiple Anti-Cancer Molecular Targets. *Angew. Chem. Int. Ed. Engl.* **56**, 3892–3896, <https://doi.org/10.1002/anie.201612583> (2017).
- Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs. *Coord. Chem. Rev.* **253**, 1670–1681, <https://doi.org/10.1016/j.ccr.2009.02.019> (2009).
- Schuh, E. *et al.* Gold(I) Carbene Complexes Causing Thioredoxin 1 and Thioredoxin 2 Oxidation as Potential Anticancer Agents. *J. Med. Chem.* **55**, 5518–5528, <https://doi.org/10.1021/jm300428v> (2012).
- Bindoli, A. *et al.* Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Vol. 253 (2009).
- Deponte, M. *et al.* Mechanistic studies on a novel, highly potent gold-phosphole inhibitor of human glutathione reductase. *J. Biol. Chem.* **280**, 20628–20637, <https://doi.org/10.1074/jbc.M412519200> (2005).
- Urig, S. *et al.* Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. *Angew. Chem. Int. Ed. Engl.* **45**, 1881–1886, <https://doi.org/10.1002/anie.200502756> (2006).
- Rohozková, D. & Steven, F. S. Gold-containing drugs and the control of proteolytic enzymes. *Br. J. of Pharmacol.* **79**, 181–189 (1983).
- Tian, S., Siu, F.-M., Kui, S. C. F., Lok, C.-N. & Che, C.-M. Anticancer gold(i)-phosphine complexes as potent autophagy-inducing agents. *Chem. Comm.* **47**, 9318–9320, <https://doi.org/10.1039/C1CC11820J> (2011).
- Roisman, F. R., Walz, D. T. & Finkelstein, A. E. Superoxide radical production by human leukocytes exposed to immune complexes: inhibitory action of gold compounds. *Inflammation* **7**, 355–362 (1983).
- Fiskus, W. *et al.* Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia. *Cancer Res.* **74**, 2520 (2014).
- Liu, N. *et al.* Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. *Oncotarget* **5**, 5453–5471 (2014).
- Marzano, C. *et al.* Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. *Free Rad. Biol. Med.* **42**, 872–881, <https://doi.org/10.1016/j.freeradbiomed.2006.12.021> (2007).
- Landini, I. *et al.* Selection and characterization of a human ovarian cancer cell line resistant to auranofin. *Oncotarget* **8**, 96062–96078, <https://doi.org/10.18632/oncotarget.21708> (2017).
- Wang, Y., Hill, K. S. & Fields, A. P. PKC δ Maintains a Tumor-initiating Cell Phenotype That Is Required for Ovarian Tumorigenesis. *Mol. Cancer Res.* **11**, 1624 (2013).
- Cassetta, M. I., Marzo, T., Fallani, S., Novelli, A. & Messori, L. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. *BioMetals* **27**, 787–791, <https://doi.org/10.1007/s10534-014-9743-6> (2014).

30. Harbut, M. B. *et al.* Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. *Proc. Natl. Acad. Sci.* **112**, 4453 (2015).
31. Hokai, Y. *et al.* Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant *Staphylococcus aureus* bacterial strains. *J. Inorg. Biochem.* **138**, 81–88, <https://doi.org/10.1016/j.jinorgbio.2014.05.008> (2014).
32. Nobili, S. *et al.* Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. *Med. Res. Rev.* **30**, 550–580, <https://doi.org/10.1002/med.20168> (2010).
33. Reddy, T. S., Privér, S. H., Mirzadeh, N. & Bhargava, S. K. Anti-cancer gold(I) phosphine complexes: Cyclic trimers and tetramers containing the P-Au-P moiety. *J. Inorg. Biochem.* **175**, 1–8, <https://doi.org/10.1016/j.jinorgbio.2017.06.010> (2017).
34. Srinivasa Reddy, T., Privér, S. H., Rao, V. V., Mirzadeh, N. & Bhargava, S. K. Gold(I) and gold(III) phosphine complexes: synthesis, anticancer activities towards 2D and 3D cancer models, and apoptosis inducing properties. *Dalton Trans.* **47**, 15312–15323, <https://doi.org/10.1039/C8DT01724G> (2018).
35. Wilton-Ely, J. D. E. T., Schier, A., Mitzel, N. W. & Schmidbaur, H. Structural diversity in gold(I) complexes of 4-sulfanylbenzoic acid. *J. Chem. Soc. Dalton Trans.* 1058–1062, <https://doi.org/10.1039/B100113M> (2001).
36. Berners-Price, S. J., Norman, R. E. & Sadler, P. J. The autoxidation and proton dissociation constants of tertiary diphosphines: relevance to biological activity. *J. Inorg. Biochem.* **31**, 197–209 (1987).
37. Berners-Price, S. J. *et al.* Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates. *J. Med. Chem.* **33**, 1386–1392, <https://doi.org/10.1021/jm00167a017> (1990).
38. Berners-Price, S. J. & Sadler, P. J. Interaction of the antitumor Au(I) complex [Au(Ph₂P(CH₂)₂PPh₂)₂]Cl with human blood plasma, red cells, and lipoproteins: 31P and 1H NMR studies. *J. Inorg. Biochem.* **31**, 267–281 (1987).
39. Jellicoe, M. M. *et al.* Bioenergetic differences selectively sensitize tumorigenic liver progenitor cells to a new gold(I) compound. *Carcinogenesis* **29**, 1124–1133, <https://doi.org/10.1093/carcin/bgn093> (2008).
40. Wedlock, L. E. *et al.* Visualising gold inside tumour cells following treatment with an antitumour gold(I) complex. *Metallomics* **3**, 917–925, <https://doi.org/10.1039/c1mt00053e> (2011).
41. Wedlock, L. E. *et al.* Dinuclear Au(I) N-heterocyclic carbene complexes derived from unsymmetrical azolium cyclophane salts: potential probes for live cell imaging applications. *Dalton Trans.* **45**, 12221–12236, <https://doi.org/10.1039/c6dt01409g> (2016).
42. Liu, J. J. *et al.* *In vitro* antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. *J. Inorg. Biochem.* **102**, 303–310, <https://doi.org/10.1016/j.jinorgbio.2007.09.003> (2008).
43. Bardaji, M., Laguna, A., Laguna, M. & Merchán, F. Methyl dithiocarbamate gold(I) and gold(III) complexes. Synthesis and reactivity with amines. *Inorganica Chim. Acta* **215**, 215–218, [https://doi.org/10.1016/0020-1693\(93\)03688-7](https://doi.org/10.1016/0020-1693(93)03688-7) (1994).
44. Altaf, M. *et al.* New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status. *Oncotarget* **8**, 490–505, <https://doi.org/10.18632/oncotarget.13448> (2016).
45. Milacic, V. *et al.* A Novel Anticancer Gold(III) Dithiocarbamate Compound Inhibits the Activity of a Purified 20S Proteasome and 26S Proteasome in Human Breast Cancer Cell Cultures and Xenografts. *Cancer Res.* **66**, 10478–10486, <https://doi.org/10.1158/0008-5472.can-06-3017> (2006).
46. Krikavová, R. *et al.* Gold(I)-triphenylphosphine complexes with hypoxanthine-derived ligands: *in vitro* evaluations of anticancer and anti-inflammatory activities. *PLoS one* **9**, e107373–e107373, <https://doi.org/10.1371/journal.pone.0107373> (2014).
47. Keter, F. K., Guzei, I. A., Nell, M., Zyl, W. E. & Darkwa, J. Phosphinogold(I) dithiocarbamate complexes: effect of the nature of phosphine ligand on anticancer properties. *Inorg. Chem.* **53**, 2058–2067, <https://doi.org/10.1021/ic4025926> (2014).
48. Barreiro, E. *et al.* Synthesis, structure and cytotoxicity of triphenylphosphinegold(I) sulfanylpropenoates. *J. Inorg. Biochem.* **102**, 184–192, <https://doi.org/10.1016/j.jinorgbio.2007.07.034> (2008).
49. Keter, F. K., Guzei, I. A., Nell, M., Zyl, W. E. V. & Darkwa, J. Phosphinogold(I) Dithiocarbamate Complexes: Effect of the Nature of Phosphine Ligand on Anticancer Properties. *Inorg. Chem.* **53**, 2058–2067, <https://doi.org/10.1021/ic4025926> (2014).
50. Abbehausen, C. *et al.* Gold(I)-Phosphine-N-Heterocycles: Biological Activity and Specific (Ligand) Interactions on the C-Terminal HIVNCP7 Zinc Finger. *Inorg. Chem.* **52**, 11280–11287, <https://doi.org/10.1021/ic401535s> (2013).
51. Yeo, C. I., Ooi, K. K. & Tiekink, E. R. T. Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy? *Molecules (Basel, Switzerland)* **23**, 1410, <https://doi.org/10.3390/molecules23061410> (2018).
52. Carboni, S. *et al.* New Variations on the Theme of Gold(III) C(wedge)N(wedge)N Cyclometalated Complexes as Anticancer Agents: Synthesis and Biological Characterization. *Inorg. Chem.* **57**, 14852–14865, <https://doi.org/10.1021/acs.inorgchem.8b02604> (2018).
53. Coronello, M. *et al.* Mechanisms of cytotoxicity of selected organogold(III) compounds. *J. Med. Chem.* **48**, 6761–6765, <https://doi.org/10.1021/jm050493o> (2005).
54. Gabbiani, C. *et al.* Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. *Metallomics* **3**, 1318–1323, <https://doi.org/10.1039/c1mt00113b> (2011).
55. Massai, L. *et al.* Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles. *Biometals* **29**, 863–872, <https://doi.org/10.1007/s10534-016-9957-x> (2016).
56. Kumar, R. & Nevado, C. Cyclometalated Gold(III) Complexes: Synthesis, Reactivity, and Physicochemical Properties. *Angew. Chem. Int. Ed. Engl.* **56**, 1994–2015, <https://doi.org/10.1002/anie.201607225> (2017).
57. Li, C. K.-L., Sun, R. W.-Y., Kui, S. C.-F., Zhu, N. & Che, C.-M. Anticancer Cyclometalated [AuIII(CAN^C)mL]n+ Compounds: Synthesis and Cytotoxic Properties. *Chem. Eur. J.* **12**, 5253–5266, <https://doi.org/10.1002/chem.200600117> (2006).
58. Harris, D. C. & Lucy, C. A. University of North Carolina at Chapel, H. & Department of, C. *Quantitative chemical analysis*. (Freeman Custom Publishing, 2016).
59. Schwerdtfeger, P., Hermann, H. L. & Schmidbaur, H. Stability of the Gold(I)–Phosphine Bond. A Comparison with Other Group 11 Elements. *Inorg. Chem.* **42**, 1334–1342, <https://doi.org/10.1021/ic026098v> (2003).
60. Imamoto, T. *et al.* Rigid P-Chiral Phosphine Ligands with tert-Butylmethylphosphino Groups for Rhodium-Catalyzed Asymmetric Hydrogenation of Functionalized Alkenes. *J. Am. Chem. Soc.* **134**, 1754–1769, <https://doi.org/10.1021/ja209700j> (2012).
61. Deak, A., Tunyogi, T., Karoly, Z., Klebert, S. & Palinkas, G. Guest escape and uptake in nonporous crystals of a gold(I) macrocycle. *J. Am. Chem. Soc.* **132**, 13627–13629, <https://doi.org/10.1021/ja105458e> (2010).
62. Schuh, W., Kopačka, H., Wurst, K. & Peringer, P. Observation of a P/M interconversion of a gold-phosphine helicate via 31P NMR. *Chem. Comm.* 2186–2187 (2001).
63. Bhargava, S. *et al.* Synthesis and structures of cyclic gold complexes containing diphosphine ligands and luminescent properties of the high nuclearity species. *Dalton Trans.* **41**, 4789–4798, <https://doi.org/10.1039/c2dt11722c> (2012).
64. Bates, P. A. & Waters, J. M. A tetrahedral complex of gold(I). The crystal and molecular structure of Au(Ph₂PCH₂CH₂PPh₂)₂Cl·2H₂O. *Inorganica Chim. Acta* **81**, 151–156, [https://doi.org/10.1016/S0020-1693\(00\)88751-4](https://doi.org/10.1016/S0020-1693(00)88751-4) (1984).
65. Healy, P. C., Loughrey, B. T., Bowmaker, G. A. & Hanna, J. V. Structural, 197Au Mössbauer and solid state 31P CP/MAS NMR studies on bis (cis-bis(diphenylphosphino)ethylene) gold(I) complexes [Au(dppey)₂]X for X = PF₆, I. *Dalton Trans.* 3723–3728, <https://doi.org/10.1039/B802496K> (2008).
66. Healy, P. C., Loughrey, B. T., Williams, M. L. & Parsons, P. G. Synthesis, structure and cytotoxicity studies of four-coordinate bis (cis-bis(diphenylphosphino)ethylene) gold(I) complexes, [Au(dppey)₂](2)X. *J. Inorg. Biochem.* **104**, 625–631, <https://doi.org/10.1016/j.jinorgbio.2010.02.003> (2010).

67. Kung, K. K. *et al.* Cyclometallated Gold(III) Complexes as Effective Catalysts for Synthesis of Propargylic Amines, Chiral Allenes and Isoxazoles. *Adv. Synth. Catal.* **355**, 2055–2070, <https://doi.org/10.1002/adsc.201300005> (2013).
68. Jong Hyun Kim, R. Tyler Mertens, Amal Agarwal, Sean Parkin, Gilles Berger, Samuel G. Awuah, Direct intramolecular carbon(sp)–nitrogen(sp) reductive elimination from gold. *Dalton Transactions* **48**(18), 6273–6282 (2019).
69. Rustad, D. S. & Gregory, N. W. The ultraviolet-visible absorption spectrum of dimeric gold(III) chloride in the gas phase. An equilibrium study of vapours formed by gold-chlorine-water mixtures. *Polyhedron* **10**, 633–643, [https://doi.org/10.1016/S0277-5387\(00\)83623-2](https://doi.org/10.1016/S0277-5387(00)83623-2) (1991).
70. Tzeng, B.-C., Chan, C.-K., Cheung, K.-K., Che, C.-M. & Peng, S.-M. Dramatic solvent effect on the luminescence of a dinuclear gold(I) complex of quinoline-8-thiolate. *Chem. Comm.* 135–136, <https://doi.org/10.1039/A606494I> (1997).
71. To, W.-P. *et al.* Luminescent Cyclometalated Gold(III) Alkyl Complexes: Photophysical and Photochemical Properties. *Inorg. Chem.* **56**, 5046–5059, <https://doi.org/10.1021/acs.inorgchem.7b00180> (2017).
72. Koshevoy, I. O. *et al.* Synthesis, structural characterization, photophysical properties and theoretical analysis of gold(I) thiolate-phosphine complexes. *Dalton Trans.* **40**, 7412–7422, <https://doi.org/10.1039/C1DT10437C> (2011).
73. Ho, S. Y., Cheng, E. C.-C., Tiekink, E. R. T. & Yam, V. W.-W. Luminescent Phosphine Gold(I) Thiolates: Correlation between Crystal Structure and Photoluminescent Properties in [R₃PAu{SC(OMe)NC₆H₄NO₂-4}] (R = Et, Cy, Ph) and [(Ph₂P-R)-PPh₂]{AuSC(OMe)NC₆H₄NO₂-4}]₂ (R = CH₂, (CH₂)₂, (CH₂)₃, (CH₂)₄, Fc. *Inorg. Chem.* **45**, 8165–8174, <https://doi.org/10.1021/ic0608243> (2006).
74. Messori, L. *et al.* Solution chemistry and cytotoxic properties of novel organogold(III) compounds. *Bioorg. Med. Chem.* **12**, 6039–6043, <https://doi.org/10.1016/j.bmc.2004.09.014> (2004).
75. Gaussian 09, Revision E.01 (Wallingford, CT, 2016).
76. Guidez, E. B. & Aikens, C. M. Time-Dependent Density Functional Theory Study of the Luminescence Properties of Gold Phosphine Thiolate Complexes. *J. Phys. Chem. A* **119**, 3337–3347, <https://doi.org/10.1021/jp5104033> (2015).
77. Fernández, E. J. *et al.* Luminescent Characterization of Solution Oligomerization Process Mediated Gold–Gold Interactions. DFT Calculations on [Au₂Ag₂R₄L₂]_n Moieties. *J. Am. Chem. Soc.* **122**, 7287–7293, <https://doi.org/10.1021/ja9942540> (2000).
78. Goolsby, A. D. & Sawyer, D. T. Electrochemistry of gold(I) and its complexes in acetonitrile. *Anal. Chem.* **40**, 1978–1983, <https://doi.org/10.1021/ac60269a020> (1968).
79. Koelle, U. & Laguna, A. Electrochemistry of Au-complexes. *Inorganica Chim. Acta* **290**, 44–50, [https://doi.org/10.1016/S0020-1693\(99\)00112-7](https://doi.org/10.1016/S0020-1693(99)00112-7) (1999).
80. Zhu, S., Gorski, W., Powell, D. R. & Walmsley, J. A. Synthesis, Structures, and Electrochemistry of Gold(III) Ethylenediamine Complexes and Interactions with Guanosine 5'-Monophosphate. *Inorg. Chem.* **45**, 2688–2694, <https://doi.org/10.1021/ic051411p> (2006).
81. Messori, L. *et al.* Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. *J. Med. Chem.* **43**, 3541–3548 (2000).
82. Pantelić, N., M. Stanković, D., Zmejkovski, B., Kaluderović, G. & Sabo, T. Electrochemical properties of some gold(III) complexes with (S,S)-R₂edda-type ligands. *Int. J. Electrochem. Sci.* **11**, 1162–1171 (2016).
83. Stillwell, W. In *An Introduction to Biological Membranes (Second Edition)* (ed William Stillwell) 315–329 (Elsevier, 2016).
84. Carter, D. C. & Ho, J. X. In *Advances in Protein Chemistry* Vol. 45 (eds Anfinsen, C. B., John, T. Edsall, Frederic M. Richards, & David S. Eisenberg) 153–203 (Academic Press, 1994).
85. Marcon, G., Messori, L., Orioli, P., Cinelli, M. A. & Minghetti, G. Reactions of gold(III) complexes with serum albumin. *Eur. J. Biochem.* **270**, 4655–4661 (2003).
86. Screnci, D. *et al.* Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. *Br. J. Cancer* **82**, 966–972, <https://doi.org/10.1054/bjoc.1999.1026> (2000).
87. McKeage, M. J. *et al.* Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. *Cancer Chemother. Pharmacol.* **46**, 343–350, <https://doi.org/10.1007/s00280000166> (2000).
88. Kotake-Nara, E., Terasaki, M. & Nagao, A. Characterization of Apoptosis Induced by Fucoxanthin in Human Promyelocytic Leukemia Cells. *Biosci. Biotechnol. Biochem.* **69**, 224–227, <https://doi.org/10.1271/bbb.69.224> (2005).
89. Hickey, J. L. *et al.* Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. *J. Am. Chem. Soc.* **130**, 12570–12571, <https://doi.org/10.1021/ja804027j> (2008).
90. Barnard, P. J. & Berners-Price, S. J. Targeting the mitochondrial cell death pathway with gold compounds. *Coord. Chem. Rev.* **251**, 1889–1902, <https://doi.org/10.1016/j.ccr.2007.04.006> (2007).
91. Boulares, A. H. *et al.* Role of Poly(ADP-ribose) Polymerase (PARP) Cleavage in Apoptosis: CASPASE 3-RESISTANT PARP MUTANT INCREASES RATES OF APOPTOSIS IN TRANSFECTED CELLS. *J. Biol. Chem.* **274**, 22932–22940, <https://doi.org/10.1074/jbc.274.33.22932> (1999).
92. Berger, N. A. Poly(ADP-Ribose) in the Cellular Response to DNA Damage. *Radiat. Res.* **101**, 4–15, <https://doi.org/10.2307/3576299> (1985).
93. Ko, H. M., Kung, K. K. Y., Cui, J. F. & Wong, M. K. Bis-cyclometallated gold(III) complexes as efficient catalysts for synthesis of propargylamines and alkylated indoles. *Chem. Comm.* **49**, 8869–8871, <https://doi.org/10.1039/c3cc44828b> (2013).
94. Kung, K. K. Y., Wong, K. F., Leung, K. C. & Wong, M. K. N-terminal alpha-amino group modification of peptides by an oxime formation-exchange reaction sequence. *Chem. Comm.* **49**, 6888–6890, <https://doi.org/10.1039/c3cc42261e> (2013).
95. Fuchita, Y., Ieda, H., Tsunemune, Y., Kinoshita-Nagaoka, J. & Kawano, H. Synthesis, structure and reactivity of a new six-membered cycloaurated complex of 2-benzoylpyridine [AuCl₂(pcp-C 1,N)] [pcp[space]=[space]2-(2-pyridylcarbonyl)phenyl]. Comparison with the cycloaurated complex derived from 2-benzylpyridine. *J. Chem. Soc. Dalton Trans.* 791–796, <https://doi.org/10.1039/A706354G> (1998).
96. Version, A. User Manual, M86-E01078. *Bruker Analytical X-Ray Systems, Madison, WI* (2006).
97. Krause, L., Herbst-Irmer, R., Sheldrick, G. M. & Stalke, D. Comparison of silver and molybdenum microfocus X-ray sources for single-crystal structure determination. *J. appl. crystallogr.* **48**, 3–10, <https://doi.org/10.1107/S1600576714022985> (2015).
98. Sheldrick, G. SADABS, Program for Bruker Area Detector Absorption Correction; University of Göttingen: Göttingen, Germany, (1997).
99. Sheldrick, G. M. Crystal structure refinement with SHELXL. *Acta Crystallogr. C* **71**, 3–8, <https://doi.org/10.1107/S2053229614024218> (2015).
100. Sheldrick, G. M. SHELXT—Integrated space-group and crystal-structure determination. *Acta Crystallogr. A* **71**, 3–8 (2015).
101. Spek, A. L. Structure validation in chemical crystallography. *Acta Crystallogr. D* **65**, 148–155 (2009).
102. Parkin, S. Expansion of scalar validation criteria to three dimensions: the R tensor. Erratum. *Acta crystallogr. A* **56**, 317–317, <https://doi.org/10.1107/S0108767300004153> (2000).
103. Lee, C., Yang, W. & Parr, R. G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. *Phys. Rev. B* **37**, 785–789, <https://doi.org/10.1103/PhysRevB.37.785> (1988).

Acknowledgements

Financial support was provided by the University of Kentucky (UK) start-up and UK IRC grant. This study made use of UK NMR facility, UK X-ray facility with funds from the MRI program (grants CHE-0319176 and CHE-1625732), Boston University Mass spectrometry facility, UK Environmental research training laboratory (ERTL), and UK flow cytometry core. We also thank Tyler R. Mertens for providing complexes 4 and 5.

Author Contributions

J.H.K. and E.R. conducted all experiments with equal contributions. S.P. solved and refined X-ray crystal structures. J.H.K. and S.G.A. designed the project, analyzed the results, prepared all figures, and wrote the main manuscript text.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-48584-5>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019